Related Experiment Video
Updated: Apr 22, 2026
08:38
Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods
Published on: September 10, 2016
25.4K
Recommendations for probiotic use in humans-a 2014 update.
1Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06850, USA. martin.floch@yale.edu.
Pharmaceuticals (Basel, Switzerland)
|October 14, 2014
Summary
This article provides updated recommendations for using probiotics in various clinical conditions, including different types of diarrhea, inflammatory bowel disorders, and allergic conditions. These guidelines aim to clarify probiotic use for healthcare professionals and patients.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Nutrition
Background:
- Probiotics are widely used globally, but their application in specific clinical conditions remains unclear.
- Expert consensus is needed to guide the appropriate use of probiotics for various health concerns.
Purpose of the Study:
- To provide updated, evidence-based recommendations for probiotic use in common clinical conditions.
- To address confusion regarding the selection of specific probiotic strains for distinct medical situations.
Main Methods:
- Convening expert workshops (2005, 2008, 2011) with leading probiotic authorities.
- Reviewing and updating recommendations based on emerging research studies.
- Compiling guidelines for conditions including diarrhea, inflammatory bowel disorders, and allergic conditions.
Main Results:
- Consensus recommendations for probiotic use in specific gastrointestinal and allergic disorders.
- Updated guidelines covering childhood diarrhea, antibiotic-associated diarrhea, necrotizing enterocolitis, inflammatory bowel disorders, irritable bowel syndrome, allergic disorders, and radiation enteritis.
Conclusions:
- The updated recommendations aim to standardize and optimize probiotic therapy across a range of clinical scenarios.
- Further expert consensus meetings are planned to continually refine probiotic application guidelines.
Related Concept Videos
01:22Probiotics
272
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
272
01:22Introduction to the Human Microbiota
136
Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity,...
136
01:30Development of Human Microbiota
58
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
58
01:17Drugs for Treatment of Diarrhea-Predominant IBS
990
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
990
01:27Microbiota of the Large Intestine
89
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
89
01:27Microbiota of the Stomach and Small Intestine
70
The human gastrointestinal (GI) tract is characterized by distinct physicochemical conditions that shape its microbial communities. Among these, the stomach presents a particularly challenging environment for microbial colonization due to its highly acidic pH, ranging from 1 to 3. This extreme acidity effectively limits microbial density. However, certain acid-tolerant microorganisms are capable of surviving in this niche. Notably, Helicobacter pylori can colonize the gastric mucosa,...
70